OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Hepatology is 95. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update	1998
Baveno VII – Renewing consensus in portal hypertension	1203
EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update	885
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma	733
Global burden of primary liver cancer in 2020 and predictions to 2040	729
EASL recommendations on treatment of hepatitis C: Final update of the series☆	711
A multisociety Delphi consensus statement on new fatty liver disease nomenclature	683
Global burden of liver disease: 2023 update	417
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study	371
COVID-19 and the liver	371
Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis	319
Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma	313
COVID-19: Discovery, diagnostics and drug development	301
Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients	283
Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials	274
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma	272
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States	268
High rates of 30-day mortality in patients with cirrhosis and COVID-19	266
Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients	258
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy	252
Systemic treatment of hepatocellular carcinoma: An EASL position paper	244
The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis	234
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores	223
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits	211
Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis	200

Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis	196
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy	194
Impact of COVID-19 on global HCV elimination efforts	193
Epidemiology and risk-stratification of NAFLD-associated HCC	189
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis	188
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis	185
Sarcopenia and frailty in decompensated cirrhosis	183
Hepatic stellate cell autophagy inhibits extracellular vesicle release to attenuate liver fibrosis	183
Single-cell genomics and spatial transcriptomics: Discovery of novel cell states and cellular interactions in liver physiology and disease biology	182
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy	177
Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction	173
EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients	172
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy	172
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis	171
Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma	169
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?	163
A new perspective on NAFLD: Focusing on lipid droplets	162
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis	158
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry	156
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort	151
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options	150
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score	149
EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis	149
Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in non-alcoholic fatty liver disease	147
Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”	145
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis	140
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?	137
Mitochondrial alterations in fatty liver diseases	137
Changing epidemiology, global trends and implications for outcomes of NAFLD	136
Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription	135
EASL Clinical Practice Guidelines on sclerosing cholangitis	134
The microbiota in cirrhosis and its role in hepatic decompensation	133
Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis	133
Peptide SMIM30 promotes HCC development by inducing SRC/YES1 membrane anchoring and MAPK pathway activation	130
Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease	128
Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease	128
Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases	128
Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial	126
Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension	120
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease	118
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma	118
Current knowledge and management of portal vein thrombosis in cirrhosis	118
COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma	117
Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease	117
Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS	117
Extracellular vesicles as biomarkers in liver diseases: A clinician's point of view	116
Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS)	114
Combined hepatocellular-cholangiocarcinoma: An update	114
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial	112
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma	111

Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019	111
Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis: A randomized controlled trial	108
Impact of non-invasive biomarkers on hepatology practice: Past, present and future	107
Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial	106
Can we use old NAFLD data under the new MASLD definition?	106
Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease	105
The changing context of hepatitis D	104
Association of liver abnormalities with in-hospital mortality in patients with COVID-19	104
HCC surveillance after SVR in patients with F3/F4 fibrosis	104
Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality	104
Endothelial GATA4 controls liver fibrosis and regeneration by preventing a pathogenic switch in angiocrine signaling	103
Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma	100
Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease	99
How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?	98
A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes	98
Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis	96
ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis	96
99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical	95
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis	95
Management of bacterial and fungal infections in cirrhosis: The MDRO challenge	95
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta	95